Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Dual Pharmacological Inhibition of IRAK1 and IRAK4 Prevents LPS Induced Monocyte Adhesion to Endothelial Cells

Version 1 : Received: 22 May 2021 / Approved: 24 May 2021 / Online: 24 May 2021 (15:09:08 CEST)

How to cite: Wu, X.; Xu, M.; Liu, Y.; Luo, S.; Zheng, X.; Xu, S.; Weng, J. Dual Pharmacological Inhibition of IRAK1 and IRAK4 Prevents LPS Induced Monocyte Adhesion to Endothelial Cells. Preprints 2021, 2021050579. https://doi.org/10.20944/preprints202105.0579.v1 Wu, X.; Xu, M.; Liu, Y.; Luo, S.; Zheng, X.; Xu, S.; Weng, J. Dual Pharmacological Inhibition of IRAK1 and IRAK4 Prevents LPS Induced Monocyte Adhesion to Endothelial Cells. Preprints 2021, 2021050579. https://doi.org/10.20944/preprints202105.0579.v1

Abstract

Inflammation associated endothelial dysfunction represents a pivotal contributor to atherosclerosis. Increasingly evidence has demonstrated that interleukin 1 receptor (IL1-R) / toll-like receptor (TLR) signaling participated in the development of atherosclerosis. Previous studies indicated the therapeutic potential of anti-inflammatory therapy in anti-atherosclerosis. The present study examined the effect of IL-1R-associated kinase 1 and 4 inhibitors (IRAK1/4i) in regulating endothelial dysfunction. IRAK1/4i showed little endothelial toxicity at concentrations from 1 to 10 μM. Inhibition of IRAK1/4 alleviated endothelial activation induced by LPS in vitro evidenced by attenuated monocyte adhesion to the endothelium. Mechanistically, blockade of IRAK1/4 ameliorated the transcriptional activity of NF-κB. Taken together, our findings demonstrated that dual inhibition of IRAK1 and IRAK4 attenuates endothelial dysfunction, suggesting pharmaceutical inhibition of IRAK1/4 might be a potential strategy to combat endothelial dysfunction and atherosclerosis.

Keywords

IRAK1; IRAK4; endothelial cells; inflammation; cardiovascular disease

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.